3/16
12:23 pm
nbp
I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
I-Mab (NBP) had its "buy" rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.
3/16
07:08 am
nbp
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]
Medium
Report
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]
3/16
07:00 am
nbp
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
Low
Report
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
3/13
06:05 am
nbp
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
Medium
Report
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
3/9
03:38 pm
nbp
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript [Seeking Alpha]
Neutral
Report
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript [Seeking Alpha]
3/9
07:32 am
nbp
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study [Yahoo! Finance]
Low
Report
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study [Yahoo! Finance]
3/9
07:00 am
nbp
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
Low
Report
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
3/3
09:39 am
nbp
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 [Yahoo! Finance]
Medium
Report
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 [Yahoo! Finance]
3/3
09:05 am
nbp
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
Medium
Report
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
3/2
07:00 am
nbp
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
Medium
Report
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
2/19
07:00 am
nbp
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
Low
Report
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
2/17
04:05 pm
nbp
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
Low
Report
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
2/6
06:45 pm
nbp
I-Mab (NASDAQ:NBP) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
Medium
Report
I-Mab (NASDAQ:NBP) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
2/6
08:03 am
nbp
I-Mab (NASDAQ:NBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ:NBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
1/20
07:00 am
nbp
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
Medium
Report
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
1/13
05:31 pm
nbp
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
1/13
05:31 pm
nbp
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
1/8
07:30 am
nbp
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Medium
Report
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
1/6
07:22 am
nbp
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer [Yahoo! Finance]
High
Report
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer [Yahoo! Finance]
1/6
07:00 am
nbp
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
High
Report
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
12/30
07:11 am
nbp
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 [Yahoo! Finance]
Low
Report
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 [Yahoo! Finance]
12/30
07:00 am
nbp
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
Low
Report
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026